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SUMMARY
Background
Acute diarrhoea is a frequent problem in children with heavy economic
burden for families and society.
Aim
To test the efﬁcacy of a new synbiotic formulation containing Lactobacillus
paracasei B21060, arabinogalactan and xilooligosaccharides in children with
acute diarrhoea.
Methods
Double-blind, randomised, placebo-controlled trial, including children (age
3–36 m) with acute diarrhoea who were allocated to placebo or synbiotic
group. Major outcome was resolution rate of diarrhoea at 72 h. Total dura-
tion of diarrhoea, daily stool outputs, stool consistency, working days lost
by parents, adjunctive medications, and hospitalisation were also assessed.
Results
We enrolled 55 children in placebo group and 52 in synbiotic group. The
two groups were similar for demographic and clinical characteristics. Reso-
lution rate of diarrhoea at 72 h was signiﬁcantly higher in synbiotic group
(67%) compared to placebo group (40%, P = 0.005). Children in synbiotic
group showed a signiﬁcant reduction in the duration of diarrhoea (90.5 h,
78.1–102.9 vs. 109.8 h, 96.0–123.5, P = 0.040), daily stool outputs (3.3, 2.8–
3.8 vs. 2.4, 1.9–2.8, P = 0.005) and stool consistency (1.3, 0.9–1.6 vs. 0.6,
0.4–0.9, P = 0.002) compared to placebo group (data expressed as mean,
95% CI). Rate of parents that missed at least one working day (41.8% vs.
15.4%, P = 0.003), rate of children that needed adjunctive medications
(25.5% vs. 5.8%, P = 0.005) or hospitalisation (10.9% vs. 0%, P = 0.014)
after the ﬁrst 72 h of treatment, were reduced in synbiotic group.
Conclusion
The synbiotic formulation studied is effective in children with acute diarrhoea.
Australian New Zealand Clinical Trials Registry (ACTRN12611000641998).
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INTRODUCTION
Acute diarrhoea is frequent in infants and children, rep-
resenting a heavy economic burden for families and soci-
ety. The standard treatment of acute diarrhoea remains
oral rehydration solution (ORS). Probiotics have gained
an important role as adjuvant therapy, so they were
included in recent guidelines on the management of
acute diarrhoea of the European Society for Pediatric
Gastroenterology, Hepatology and Nutrition (ESP-
GHAN) and the European Society for Pediatric Infec-
tious Disease (ESPID).1 The guidelines state that
‘probiotics may be an effective adjunct to the manage-
ment of diarrhea’ but that ‘only the use of probiotic
strains with proven efﬁcacy and in appropriate doses is
suggested’. A large number of studies, including rando-
mised and controlled trials and metanalyses reported an
anti-diarrhoeal effects of probiotics, particularly in chil-
dren,2–12 although limited data were available on the efﬁ-
cacy of products containing probiotics associated with
prebiotics namely synbiotics.13 It has been demonstrated
that prebiotics improve probiotics strain survival, by
making speciﬁc substrates readily available for their fer-
mentation, with a clear advantage to the host.13 Synbiot-
ics may be given as separate supplements or may exist in
functional food as additives.13 The aim of this study was
to investigate the efﬁcacy of a synbiotic formulation con-
taining Lactobacillus paracasei B21060 plus arabinogalac-
tan and xilooligosaccharides in the treatment of children
with acute diarrhoea.
METHODS
Study design
We performed a prospective, randomised, double-blind,
placebo-controlled trial in collaboration with family pae-
diatricians, who care for children up to 14 years of age
in the Italian Public Health System. The study protocol
was reviewed and approved by the Ethics Committee of
the University Federico II of Naples and registered in
the Australian New Zealand Clinical Trials Registry
(ACTRN12611000641998), and it was illustrated and dis-
cussed during three meetings with all physicians involved
in the research.
Participants
From November 2010 to March 2011, all children 3–
36 months of age consecutively observed in the paedia-
trician ofﬁces presenting with diarrhoea lasting less than
24 h with mild-moderate dehydration were considered
eligible for the study. Diarrhoea was deﬁned as three or
more outputs of loose or liquid stools/day.8 At the enrol-
ment, after the initial assessment, the paediatricians were
asked to estimated the degree of dehydration of each
patient by using a seven-point Likert scale and to deter-
mine their capillary reﬁll time by using standard clinical
techniques (<2 s or >2 s) as used in a previous
study.14, 15 Exclusion criteria were diarrhoea lasting more
than 24 h, malnutrition as judged by a body weight/
height ratio below the ﬁfth percentile, clinical signs of
severe dehydration, clinical signs of a coexisting severe
acute infection (meningitis, sepsis, pneumonia), immu-
nodeﬁciency, underlying severe chronic diseases, cystic
ﬁbrosis, food allergy or other chronic gastrointestinal dis-
eases, endocrinopathy, use of pre/probiotics or antibiotics
or any anti-diarrhoeal medication in the previous
3 weeks. Written informed consent was obtained from
parents of the enrolled children. Microbiologic and other
laboratory investigations were performed only in the
presence of speciﬁc clinical reasons.
Intervention
Enrolled patients were randomly allocated to placebo
group (one sachet dissolved in 50 mL of water b.d. for
5 days) or synbiotic group (one sachet dissolved in
50 mL of water b.d. for 5 days containing Lactobacillus
paracasei B21060, 2.5 9 109 CFU, plus arabinogalactan,
500 mg, and xilooligosaccharides, 700 mg b.d.; Flortec
Bracco, Milan, Italy). The parents were instructed to
rehydrate orally their children with hypotonic ORS in 3–
4 h and then to administer ORS for dehydration preven-
tion until end of symptoms, and to refeed the child with
a normal appropriate-for-age diet including full strength
lactose-containing formula or cow's milk (for guidelines
see reference 1).
Outcome
Primary outcome was the rate of resolution of diarrhoea
at 72 h of treatment. Diarrhoea was considered to have
stopped after a patient had passed the last abnormal
(loose or liquid) stools preceding a normal stool output,
as applied in a previous study.8
Randomisation and blinding
Patients were allocated to each group according to a
computer-generated randomisation list. The researcher
responsible for enrolling patients allocated the next avail-
able number on entry in the trial. Each patient received
white aluminium foil sachets contained in a blank paper
box blind code labelled. The aspect of paper box, sachets
and organoleptic characteristics of placebo or active
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treatment were identical. The parents of enrolled chil-
dren were instructed to record daily on a speciﬁc form:
time, number and consistency (graded as 0: normal, 1:
loose, 2: semi liquid, and 3: liquid), faecal outputs;
missed working days, use of other medications, hospital
admission; and adverse events. The investigators collect-
ing the reporting forms were blind to the patient's treat-
ment assignment, which was concealed until statistical
analysis was completed.
Sample size
To obtain a power of the study of 85% (type 1
error = 0.05; two-tailed test), considering a difference of
30% (40% vs. 70%) in the rate of resolution of diarrhoea
at 72 h between the two groups, 48 patients in each
group were estimated. We enrolled 55 patients per group
considering a possible drop out up rate as high as 15%.
Statistical analysis
Statistical analysis was performed by a statistician blind
to preparations received by children in the two groups.
Because of Gaussian distribution assessed by the
Kolmorogov–Smirnov test, continuous variables were
expressed as means and 95% CI. For categorical vari-
ables, the Pearson chi-square test or Fisher's exact test
was performed as appropriate. The two groups were com-
pared for continuous variables by t-test for equality of
means. Kaplan–Meier method was used to estimate the
probability of diarrhoea at 72 h in each study group, and
the resulting functions were compared with the log-rank
test. Analyses were conducted on an intention-to-treat
basis. Patients allocated in each group were considered
available for ITT analysis when received at least two doses
of active treatment or placebo. All tests of signiﬁcance
were two sided. A P value of <0.05 was considered signiﬁ-
cant. The statistical analysis was performed using the
SPSS software package for Windows (release 16.0.0; SPSS
Inc., Chicago, IL, USA) and Starts Direct (release 2.6.6).
RESULTS
Figure 1 shows the ﬂow of children through the study.
The demographic and clinical characteristics of the chil-
dren enrolled in the two groups were similar at the base-
line (Table 1). No infants were breastfed. No patients in
the study had hematochezia. Resolution of diarrhoea at
72 h was higher in synbiotic group (67%) than in pla-
cebo group (40%; OR 0.324, 95% CI 0.147–0.715;
P = 0.005). The number of daily stool outputs and con-
sistency resulted signiﬁcantly reduced in synbiotic group
compared with placebo group at 72 h of treatment
Assessed for eligibility (n = 112)
Declined to participate (n = 2)
Enrollment (n = 110)
Synbiotic groupPlacebo group
Allocated to intervention (n = 55) Allocated to intervention (n = 55)
Received allocated intervention (n = 55)
Received allocated intervention (n = 52)
Did not receive allocated intervention (n = 3)
Discontinued intervention
(n = 3, hospitalisation for
Worsening symptoms)
Subjects completed (n = 52)
Data analysed (n = 55)
Subjects completed (n = 48)
Data analysed (n = 52)
Lost to follow-up (n = 4)
Figure 1 | Flow of children through the study.
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(Table 2). The total duration of diarrhoea was reduced
in patients in synbiotic group compared to placebo
group (Table 2). Probability of diarrhoea within 72 h of
treatment was higher in placebo group compared with
synbiotic group (Figure 2). The rate of parents missed at
least one working day was signiﬁcantly higher in placebo
group (Table 2). Adjunctive medications within the 72 h
were not used by any patient, whereas after the ﬁrst
72 h the use of additional treatments were higher in sub-
jects in placebo group than in children in synbiotic
group (Table 2). In particular, the medications used were
(no. of patients in placebo group vs. no. of patients in
synbiotic group): probiotics (7 vs. 0), diosmectite (3 vs.
3), racecadotril (3 vs. 0), and domperidone (1 vs. 0). The
rate of patients requiring hospitalisation because of wors-
ening of symptoms was slightly but not signiﬁcantly
higher in placebo group (Table 2). No adverse event was
observed in the two groups.
DISCUSSION
We demonstrated that a new synbiotic formulation con-
taining L. paracasei B21060 plus arabinogalactan and
xilooligosaccharides is effective in the treatment of acute
diarrhoea in children. This synbiotic formulation resulted
in the ability to reduce the duration and severity of
diarrhoea. The results of the synbiotic tested in this trial
are comparable with those reported in the recent Coch-
rane review, focused on the efﬁcacy of probiotics in
acute diarrhoea, showing a signiﬁcant reduction of: diar-
rhoea duration of ~ 24 h (95% CI 15.9 + 33.6 h;
Table 1 | Baseline features of the children allocated to study treatments
Placebo group (n = 55) Synbiotic group (n = 52) P
Age, m 20.9 (17.6–24.3) 20.0 (16.7–23.5) 0.711
Body weight, kg 11.9 (10.9–12.9) 12.2 (11.2–13.3) 0.704
Male, n (%) 31 (56.4) 27 (51.9) 0.645
Duration of symptoms before treatment, h 8.4 (8.0–8.7) 8.3 (8.0–8.7) 0.965
Presence of vomiting, n (%) 15 (27.3) 13 (25.0) 0.807
Degree of dehydration*
Mild 23 (41.8) 25 (48.1) 0.515
Moderate 32 (58.2) 27 (51.9) 0.515
Data are expressed as mean (95% CI) when not speciﬁed.
* Assessed according to standardised criteria, as previously described.14, 15
Table 2 | Secondary outcomes in the two groups of the study
Placebo group (n = 55) Synbiotic group (n = 52) P
Total diarrhoea duration 109.8 (96.0–123.5) 90.5 (78.1–102.9) 0.040
Number of stool outputs (from 48 to 72 h after treatment) 3.3 (2.8–3.8) 2.4 (1.9–2.8) 0.005
Stool consistency score (from 48 to 72 h after treatment) 1.3 (1.0–1.6) 0.6 (0.4–0.9) 0.002
Adjunctive medication, n (%) 14 (25.5) 3 (5.8) 0.005
Rate of patients requiring hospitalization, n (%) 6 (10.9) 0 (0) 0.014
Rate of parents missed at least one working day, n (%) 23 (41.8) 8 (15.4) 0.003
Data as expressed as mean (95% CI) when not speciﬁed.
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Figure 2 | Kaplan–Meyer curve showed a signiﬁcant
difference (log-rank test, P = 0.001) in the probability
of unresolved diarrhoea at 72 h after starting treatment
between placebo or synbiotic formulation (containing
Lactobacillus paracasei B21060 plus arabinogalactan and
xilooligosaccharides).
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n = 4555, trials = 35) and diarrhoea lasting more than
4 days (risk ratio 0.41; 0.32–0.53; n = 2853, trials = 29).2
In this Cochrane review and in a recent clinical report
by the Committee of Nutrition Section Gastroenterology
Hepatology and Nutrition of the American Academy of
Pediatrics, Lactobacillus GG (LGG) resulted in the most
effective probiotic in the treatment of acute diar-
rhoea.2, 13 Interestingly, in a recent study Grossi et al.
compared the therapeutic efﬁcacy of the same synbiotic
preparation investigated in our study with LGG, and the
synbiotic proved to be more effective than LGG in the
treatment of acute diarrhoea in adult treated at primary
care setting.16
Numerous pre-pro-synbiotic preparations become
available on the market every year and it could be difﬁcult
for a physician to select effective products for the treat-
ment of different disorders. Because of strain, product
and age speciﬁcities (especially for products containing
mixtures of probiotic strains and prebiotics), and in order
to be in agreement with recommendations of ofﬁcial and
scientiﬁc organizations, it is recommended to perform
randomised controlled trials with each commercialized
product.17 The results of our study support the clinical
utility of this new synbiotic preparation in the treatment
of ambulatory paediatric patients with acute diarrhoea.
According to recent guidelines for the management of
ambulatory children with acute diarrhoea, we did not
investigate the aetiology of diarrhoea in our patients.
However, considering epidemiologic data and that in
Italy the national vaccination programme does not
include Rotavirus universal vaccination, it is possible to
speculate that the majority of patients presented acute
diarrhoea induced by viral pathogens, in particular Rota-
virus.18–21 Probiotics exert a wide range of possible
mechanisms of action against intestinal pathogens.22
There are three general classes of anti-pathogenic mecha-
nisms: direct antagonism, immune-modulation and
exclusion.23 The most recent research focused on the role
of probiotic microorganisms and their secretion products
in strengthening and modulating, through other mecha-
nisms, the both congenital and adaptive immune
response in the host. After the observation that immune
and epithelial cells can discriminate among different
microbial species through the activation of Toll-like
receptors,24 the hypothesis emerged that probiotics might
exert protective effect by modulating immunologic activ-
ity and epithelial function, both in the small and large
intestine.25, 26 A recent study has highlighted the striking
difference among different species and strains of lactoba-
cilli modulating the immune and inﬂammatory
response.27 These authors compared the immunological
properties of L. plantarum NCIMB8826, LGG and L. pa-
racasei B21060, studying the stimulating effects of these
different strains on dendritic cells either directly through
a co-culture or indirectly through conditioning of an epi-
thelial intermediary. In this study, the authors emphas-
ised, at variance with LGG and L. plantarum, the
immunomodulatory effect of L. paracasei B21060 that
once in the intestine may act directly on intraepithelial
dendritic cells limiting their ability to induce inﬂamma-
tion in the presence of potent inﬂammatory pathogens.
Preliminary data suggested that some immunomodula-
tory effect of L. paracasei B 21060 could be exerted by
soluble factors produced by the bacteria.27
Lactobacillus paracasei B 21060 is a novel strain of
lactobacillus isolated from the faeces of breastfed babies
and its non-occasional presence in the normal intestinal
microﬂora was established after extensive monitoring by
genetic identiﬁcation methods28 but future research is
needed to better deﬁne the possible mechanisms of
action of this probiotic strain in the treatment of acute
diarrhoea.
Up to now, few data are available on the efﬁcacy of
synbiotics in the treatment of acute diarrhoea. Nondige-
stable carbohydrates seem to be unable to reduce the
duration of diarrhoea29 but they could confer additional
beneﬁts over a probiotic by normalising more rapidly
intestinal microﬂora perturbation during enteric infection
and stabilizing the effect of probiotics.30–33 In a recent
study, Drakoularakou et al. demonstrated the effective-
ness of a prebiotic galacto-oligosaccharide mixture (B-
GOS) on the severity and/or incidence of traveller's diar-
rhoea.34 The results of a in vitro screening study that
aimed identifying promising prebiotic and synbiotic can-
didates for the diarrhoea treatment, indicated that differ-
ent types of microorganisms and microbial groups are
able to ferment the tested oligosaccharides (xylo-oligo-
saccharides (XOS), xylo, galacto-oligosaccharides, fructo-
oligosaccharide, polydextrose, lactitol, gentiobiose and
pullan) in pure cultures, and that some of these com-
pounds could be useful in the development of new prod-
uct candidates as they promoted the growth of few,
beneﬁcial probiotic microbes in the competitive environ-
ment of the colon. XOS compounds enhanced the
growth of a limited number of microbes, especially B.
lactis.35 Further prospective controlled trials should be
planned to establish if the results obtained in this study
are not due only to the probiotic component of the syn-
biotic. Our results suggest a positive cost-efﬁcacy ratio in
the use of this synbiotic preparation in the treatment of
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acute diarrhoea in children. We observed a signiﬁcant
reduction in parents’ working day loss and in medication
use, the two most important parameters contributing up
to 85% of the total cost of a single episode of acute diar-
rhoea.36 One single therapeutic course using this new
commercially available synbiotic product costs about 10
Euro. One single episode of acute diarrhoea in children
in Italy costs about 137 Euro. Of this about 116 Euro are
related to working day loss by the parents and additional
medications use. The average cost of the commercially
available probiotic products on the market is equal to
the cost of this synbiotic product. In this light, the use of
this synbiotic could be responsible for substantial reduc-
tion of the cost related to acute diarrhoea.
In conclusion, our results showing that the new synbi-
otic preparation composed by L. paracasei B21060 plus
arabinogalactan and xilooligosaccharides signiﬁcantly
reduces the duration and severity of diarrhoea of likely
infection origin suggest a new possible effective and cost
saving therapeutic strategy for the treatment of ambula-
tory children with this very common disease.
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